Home
Home

Merck KGaA

Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine

Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
Bloomberg

ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine

ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine
TheStreet.com

Germany's Merck KGaA sees profit rise 54 percent in Q1 helped by higher prices for key drug

Germany's Merck KGaA sees profit rise 54 percent in Q1 helped by higher prices for key drug
Yahoo/AP

Merck KGaA Boosts Stock With Job Cuts Amid Drug Drought

Merck KGaA Boosts Stock With Job Cuts Amid Drug Drought
Bloomberg

Merck KGaA Profit Beats Analyst Estimates on Cost Cuts

Merck KGaA Profit Beats Analyst Estimates on Cost Cuts
Bloomberg

Merck KGaA signs $225 million personalized MS drug deal

Merck KGaA signs $225 million personalized MS drug deal
Pharma Times, UK

2013 Should Be Interesting for Multiple Sclerosis Drugs

2013 Should Be Interesting for Multiple Sclerosis Drugs
Motley Fool

Germany's Merck suffers setback with cancer drug

Germany's Merck suffers setback with cancer drug
Yahoo/AP

Merck KGaA to resist lure of potential proceeds from OTC sale

Merck KGaA to resist lure of potential proceeds from OTC sale
Reuters

Merck KGaA expects to publish Stimuvax data in Q1 2013

Merck KGaA expects to publish Stimuvax data in Q1 2013
Reuters